ALEC · XBRL financial data

Alector financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ALEC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	21,098	—	133,600	97,100	100,600	21,045
Revenue from contracts with customers	21,098	207,085	133,617	97,062	100,558	21,045
Research and development	156,869	189,407	210,418	192,115	185,940	123,065
General and administrative	59,403	55,038	61,033	56,687	59,615	53,987
Total operating expenses	216,272	244,445	271,451	248,802	245,555	177,052
Operating income (loss)	(195,174)	(37,360)	(137,834)	(151,740)	(144,997)	(156,007)
Other income (expense)	4,946	1,031	7,778	26,561	26,076	13,246
Income tax expense (benefit)	0	0	3,254	5,212	128	168
Net income (loss)	(190,228)	(36,329)	(133,310)	(130,391)	(119,049)	(142,929)
Earnings per share, basic USD per share	(2.45)	(0.45)	(1.62)	(1.56)	(1.23)	(1.39)
Earnings per share, diluted USD per share	(2.45)	(0.45)	(1.62)	(1.56)	(1.23)	(1.39)
Weighted average shares, basic thousands of shares	77,759	80,417	82,468	83,734	96,588	102,999
Weighted average shares, diluted thousands of shares	77,759	80,417	82,468	83,734	96,588	102,999

Fiscal years (ALEC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	49,969	329,152	154,323	74,555	33,021	65,802
Marketable securities	363,339	406,099	558,528	474,306	380,376	190,222
Prepaid and other current assets	8,203	7,071	10,997	16,946	11,420	10,428
Total current assets	421,511	749,713	726,435	565,807	424,817	266,452
Property and equipment, net	30,181	27,330	25,521	21,861	17,145	10,841
Right-of-use asset	32,470	30,569	27,811	25,195	19,951	13,712
Total assets	488,251	814,658	787,648	621,827	468,303	293,237
Accounts payable	3,004	4,749	4,189	3,775	2,215	1,691
Accrued liabilities	22,538	27,460	27,771	30,378	28,890	19,299
Current portion of long-term debt	—	—	—	—	—	366
Total current liabilities	68,088	139,555	93,809	177,948	125,059	69,503
Long-term debt	—	—	—	0	9,389	9,323
Lease liability, non-current	43,744	39,806	35,268	30,456	24,376	17,488
Total liabilities	220,721	513,934	573,206	487,669	341,503	262,588
Accumulated deficit	(410,048)	(446,377)	(579,687)	(710,078)	(829,127)	(972,056)
Total stockholders' equity	267,530	300,724	214,442	134,158	126,800	30,649
Total liabilities and equity	488,251	814,658	787,648	621,827	468,303	293,237
Common shares outstanding (cover page) thousands of shares	79,584	82,040	83,028	95,749	99,086	110,363

Fiscal years (ALEC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(190,228)	(36,329)	(133,310)	(130,391)	(119,049)	(142,929)
Stock-based compensation	30,522	40,785	46,146	42,798	39,463	26,658
Net cash from operating activities	(166,734)	298,551	(20,329)	(184,162)	(229,905)	(184,031)
Purchases of property and equipment	5,032	3,247	4,117	2,381	1,255	41
Net cash from investing activities	(105,051)	(49,663)	(159,014)	101,918	107,131	196,597
Proceeds from issuing common stock	—	—	—	—	71,108	19,983
Net cash from financing activities	232,113	30,295	4,514	2,550	81,540	20,215
Net change in cash	(39,672)	279,183	(174,829)	(79,694)	(41,234)	32,781

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Alector	59,915	3,320	(34,217)*	111.7M	5.1 quarters	Q2 FY26 10-QJun 30, 2026
Protalix BioTherapeutics	27,420	19,896	(10,400)*	80.6M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
Fate Therapeutics	32,429	2,082	(23,400)	119.8M	6.6 quarters	Q2 FY26 10-QJun 30, 2026
Caribou Biosciences	26,194	1,499	(22,787)*	107.2M	4.9 quarters	Q2 FY26 10-QJun 30, 2026
Protara Therapeutics	17,076	not reported	(15,389)*	59.1M	9.3 quarters	Q2 FY26 10-QJun 30, 2026
TuHURA Biosciences	996	not reported	(8,634)*	63.7M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Enanta Pharmaceuticals	33,419	14,359	(9,972)*	29.1M	19.0 quarters	Q3 FY26 10-QJun 30, 2026
Kodiak Sciences	125,903	not reported	(46,238)*	62.8M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
Galectin Therapeutics	13,269	not reported	(2,439)*	100.8M	5.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.